

## CRO

[View the current CRO Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/21419-CRO.html) (<http://www.bioportfolio.com/biorporate/21419-CRO.html>)

### Contact Details:

256 Bunn Drive Suite 6

Princeton

New Jersey

08540

United States of America

Tel: 1 609 731 2225

Fax:

Email: [info@cro-rct.ru](mailto:info@cro-rct.ru)

RCT Global is a Regional CRO located in Saint-Petersburg Russia, performing clinical research services across the breadth of the Russian Federation, former Soviet Republics and Eastern Europe.

Since 2001 RCT Global has expanded it's experience across numerous therapeutic areas working with international clients from across the globe. Whether you are looking for full clinical support to include site selection, monitoring, project management, regulatory, import/export, drug storage, and medical writing; or only interested in an individual service to address an urgent need, you can count on us to handle your requirements professionally and completely.

The Company was established by a group of research professionals focused on introducing Russian patients to Western medicines that previously were out of reach for the majority of the Russian population. RCT Global understands the synergistic benefits of providing Russian patients access to both current and experimental medicines while at the same time providing Western Pharmaceutical and Biotech Companies access to a large and compliant patient population.

### Recent Publications by CRO:



- [Institutional shared resources and translational cancer research.](#)

*The development and maintenance of adequate shared infrastructures is...*5th November, 2009  
Centro di Riferimento Oncologico, IRCCS, I-33081 Aviano PN Aviano, Italy.- J Transl Med. 2009 Jun 29;7:54. ([DOI Direct Link](#))

- [Galectin-10, eosinophils, and celiac disease.](#)

*Celiac disease (CD) is a chronic intestinal disease caused by intolerance...*30th October, 2009  
Experimental and Clinical Pharmacology Unit, Istituto Di Ricovero e Cura a- Ann N Y Acad Sci. 2009 Sep;1173:357-64. ([DOI Direct Link](#))

- [Clonal CD27+ CD19+ B cell expansion through inhibition of FC gammaIIIR in HCV\(+\) cryoglobulinemic patients.](#)

- Persistent HCV infection may be associated with extrahepatic...*30th October, 2009  
Experimental and Clinical Pharmacology Unit, DOMERT, Molecular Oncology- Ann N Y Acad Sci. 2009 Sep;1173:326-33. ([DOI Direct Link](#))
- [Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region \(VK\) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations.](#)  
*Autoimmune type-II cryoglobulinemia (II-MC) is sustained by hepatitis C...*30th October, 2009  
Experimental and Clinical Pharmacology Unit, Dipartimento di Oncologia- Ann N Y Acad Sci. 2009 Sep;1173:152-60. ([DOI Direct Link](#))
  - [Distinct spatio-temporal Ca<sup>2+</sup> signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow.](#)  
*We studied how integrin alpha2beta1 and glycoprotein VI (GPVI) contribute...*29th October, 2009  
Department of Laboratory Medicine, Centro di Riferimento Oncologico (CRO)- Blood. 2009 Sep 24;114(13):2793-801. Epub 2009 Jul 21. ([DOI Direct Link](#))
  - [Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.](#)  
*OBJECTIVES: To provide survival estimates of Italian people with AIDS...*25th September, 2009  
Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico,- J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):99-105. ([DOI Direct Link](#))
  - [No risk of maternal EBV infection for childhood leukemia.](#)  
*We performed a large nested case-control study within the Finnish and...*17th September, 2009  
Microbiology-Immunology and Virology Unit, Centro di Riferimento- Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2790-2. Epub 2009 Sep ([DOI Direct Link](#))
  - [Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study.](#)  
*BACKGROUND: Data on colorectal cancer (CRC) in HIV-positive patients are...*27th August, 2009  
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.- Onkologie. 2009 Jun;32(6):319-24. Epub 2009 May 14. ([DOI Direct Link](#))
  - [Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.](#)  
*We previously reported that exosomal nanoparticles secreted by human...*26th August, 2009  
INSERM UMR CRO, Aix-Marseille Universite, France.- Int J Cancer. 2009 Sep 1;125(5):1016-26. ([DOI Direct Link](#))
  - [Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.](#)  
*PURPOSE: The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are...*4th August, 2009  
Experimental and Clinical Pharmacology Unit, Centro di Riferimento- Clin Cancer Res. 2009 May 15;15(10):3550-6. ([DOI Direct Link](#))
  - [Identification of proteins associated to multi-drug resistance in LoVo human colon cancer cells.](#)  
*Multi-drug resistance (MDR) limits the effectiveness of chemotherapy....*4th August, 2009  
Experimental and Clinical Pharmacology Unit, CRO Centro di Riferimento- Int J Oncol. 2009 May;34(5):1281-9.
  - [Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma.](#)  
*BACKGROUND: The role of low doses of cisplatin and concomitant...*17th July, 2009  
Radiation Oncology Division, Centro di Riferimento Oncologico (National- Cancer. 2009 Jun 1;115(11):2464-71. ([DOI Direct Link](#))
  - [Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.](#)  
*Leiomyosarcoma of the parotid gland is a rare tumor with only six cases...*16th July, 2009  
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.- J Chemother. 2009 Apr;21(2):215-8.
  - [Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.](#)  
*This is a mono-institutional analysis of the clinical features...*6th May, 2009  
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.- J Med Virol. 2009

May;81(5):888-96. ([DOI Direct Link](#))

- [Two-dimensional gel proteome reference map of human small intestine.](#)

*ABSTRACT: BACKGROUND: The small intestine is an important human organ that...* 21st March, 2009  
Experimental and Clinical Pharmacology, CRO Centro di Riferimento- Proteome Sci. 2009 Mar  
19;7:10. ([DOI Direct Link](#))

#### Press Releases on CRO:

<a href="#">Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.</a>	18th November, 2009	Covance Inc.	<i>PRINCETON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug development services, announced today that it entered into a biomarker alliance and services</i>
<a href="#">SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise</a>	17th November, 2009	SIRO Clinpharm	<i>MUMBAI, India, Nov. 17 /PRNewswire/ -- SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early</i>
<a href="#">Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors</a>	13th November, 2009	Encorium Group, Inc.	<i>BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many</i>
<a href="#">ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 2009</a>	13th November, 2009	ReSearch Pharmaceutical Services, Inc.	<i>-- Net income before provision for income taxes for the third quarter of 2009 of \$2.2 million increased \$0.9 million from \$1.3 million for the third quarter of 2008. Net income</i>
<a href="#">Pharmos Corporation Reports 2009 Third Quarter Results</a>	12th November, 2009	Pharmos Corporation	<i>ISELIN, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Third</i>

- [Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc](#)  
*PR Newswire: Nov 23 2009 12:45AM Matching: cro*
- [China Biotech Week in Review: CROs Consolidating](#)  
*Seeking Alpha: Nov 22 2009 2:12PM Matching: cro*
- [Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors](#)  
*Pharma Live: Nov 22 2009 3:01PM Matching: cro*
- [Ecron Acunova opens new office in Russia to tap clinical trials opportunities](#)  
*PharmaBiz: Nov 21 2009 2:42AM Matching: cro*
- [PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China](#)  
*Genetic Engineering News: Nov 20 2009 3:58AM Matching: cro*
- [Drug Industry Positive About 2010](#)  
*Pharmaceutical Technology: Nov 20 2009 12:09PM Matching: cro*
- [MedPoint Names James Mulvihill Director of Business Development for research Services Group](#)  
*Pharmacy Choice: Nov 20 2009 9:42AM Matching: cro*
- [Perfect the CRO selection and management process - and guarantee trial success](#)  
*Pharmacy Choice: Nov 19 2009 4:36AM Matching: cro*
- [KLIXAR Joins Health Decisions' Global Network of CROs Advocating Higher Efficiency Standards](#)  
*Pharma Live: Nov 19 2009 6:45AM Matching: cro*
- [Encoriums Q3 operating loss drops to US\\$616,713](#)  
*Pharma Times: Nov 19 2009 4:33PM Matching: cro*
- [PPD Acquires CRO BioDuro to Further Expand Its Outsourcing Capabilities in China](#)  
*Genetic Engineering News: Nov 19 2009 4:13PM Matching: cro*
- [Further boost for CovanceEURs biomarker offering in RBM deal](#)  
*Outsourcing Pharma: Nov 19 2009 2:13PM Matching: cro*
- [Further boost for CovanceEURs biomarker offering in RBM deal](#)  
*Outsourcing Pharma: Nov 19 2009 2:13PM Matching: cro*
- [Further boost for CovanceEURs biomarker offering in RBM deal](#)  
*Outsourcing Pharma: Nov 19 2009 2:13PM Matching: cro*
- [Further boost for CovanceEURs biomarker offering in RBM deal](#)  
*Outsourcing Pharma: Nov 19 2009 2:12PM Matching: cro*

**CRO Clinical Trials:**



- [Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to

your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

